Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E MacIntyre

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 1, 1995
A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivoD S Fletcher, L Agarwal, K T Chapman, et al.
Journal of Medicinal Chemistry|March 17, 1995
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophanA M MacLeod, M A Cascieri, K J Merchant, et al.
Journal of Lipid Mediators|June 1, 1993
MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factorS B Hwang, M H Lam, D M Szalkowski, et al.
Journal of Medicinal Chemistry|November 24, 1995
Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane human NK1 antagonistsC J Swain, E M Seward, M A Cascieri, et al.
Life Sciences|February 24, 1998
Desensitization of beta3-adrenergic receptor-stimulated adenylyl cyclase activity and lipolysis in ratsP P Vicario, M R Candelore, M T Schaeffer, et al.
Journal of Medicinal Chemistry|April 26, 1996
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonistJ J Hale, S G Mills, M MacCoss, et al.
Neuropeptides|January 27, 1999
Melanocortin mediated inhibition of feeding behavior in ratsB Murphy, C N Nunes, J J Ronan, et al.
Neuropharmacology|January 1, 1996
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferretsF D Tattersall, W Rycroft, B Francis, et al.
Neuropharmacology|March 23, 2000
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferretsF D Tattersall, W Rycroft, M Cumberbatch, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2000
Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophoreR J Mathvink, J S Tolman, D Chitty, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 1, 1995
A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivoD S Fletcher, L Agarwal, K T Chapman, et al.
Journal of Medicinal Chemistry|March 17, 1995
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophanA M MacLeod, M A Cascieri, K J Merchant, et al.
Journal of Lipid Mediators|June 1, 1993
MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factorS B Hwang, M H Lam, D M Szalkowski, et al.
Journal of Medicinal Chemistry|November 24, 1995
Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane human NK1 antagonistsC J Swain, E M Seward, M A Cascieri, et al.
Life Sciences|February 24, 1998
Desensitization of beta3-adrenergic receptor-stimulated adenylyl cyclase activity and lipolysis in ratsP P Vicario, M R Candelore, M T Schaeffer, et al.
Journal of Medicinal Chemistry|April 26, 1996
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonistJ J Hale, S G Mills, M MacCoss, et al.
Neuropeptides|January 27, 1999
Melanocortin mediated inhibition of feeding behavior in ratsB Murphy, C N Nunes, J J Ronan, et al.
Neuropharmacology|January 1, 1996
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferretsF D Tattersall, W Rycroft, B Francis, et al.
Neuropharmacology|March 23, 2000
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferretsF D Tattersall, W Rycroft, M Cumberbatch, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2000
Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophoreR J Mathvink, J S Tolman, D Chitty, et al.
Pageof 11